Sweden · Funded startup

Who invested in OncoZenge

2 rounds we have observed, with the 0 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Raised 2 months ago

Funding summaryUpdated 26 Oct 2026

$3.9Mraised across 2 rounds since 2025, from 2 sources

$790KDebt$3.1MRound
Latest round
Round, $3.1MSept 2026
Step-upi
3.9×
Investors
0
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2026
$790KDebt$3.1MRound
First round
Debt, $790K
Jul 2025
Biggest round
$3.1M
Round · Sept 2026
Between rounds
14 months
from the last two

The rounds

  1. Sept 2026
    Round$3.1M

    No investor was named in the report.

    Source recorded

  2. Jul 2025
    Debt$790K

    No investor was named in the report.

    Source recorded

Founders and team

From OncoZenge's own website: 9 on the team.

  • Stian KildalCEO
  • Michael OwensChief Financial Officer (CFO)
  • Linda NordHead of Regulatory AFFAIRS
  • Tuulikki LindmarkHead of CMC / Product
  • Anna AsplindPhase III Program Manager
  • Anna-Karin AbelsonClinical Research Manager
  • Daniel EhrenstråhleChairman of the board
  • Marie MooresBoard member
  • Paul MurtaghBoard member

AdvisersIntellectual Property

Quick answers about OncoZenge

How much has OncoZenge raised?

OncoZenge has raised $3.9M across 2 rounds since 2025.

When did OncoZenge last raise?

OncoZenge's most recent round was an Undisclosed round of $3.1M in Sept 2026.

What was OncoZenge's biggest round?

Its most recent round, $3.1M in Sept 2026, is also its largest on record.

What stage is OncoZenge at?

OncoZenge's latest named round is an Undisclosed round, in Sept 2026.

Where is OncoZenge based?

OncoZenge is based in Sweden.

Companies like OncoZenge

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.